JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) received written notice from Janssen, a unit of Johnson & Johnson (NYSE:JNJ), to terminate their rights to JNJ-75220795, now called…
B. Riley Securities Maintains Buy on Arrowhead Pharma, Lowers Price Target to $55
B. Riley Securities analyst Mayank Mamtani maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $59 to $55.
Baird Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $58
Baird analyst Joel Beatty maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and lowers the price target from $60 to $58.
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600.
Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.
Energizer, Children’s Place And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Arrowhead Pharmaceuticals Announces $25M Milestone Payment From Amgen
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced a $25M milestone payment from Amgen (NASDAQ:AMGN). This milestone was triggered by the first subject enrolled in Amgen's Phase 3 trial of
Jefferies Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $75
Jefferies analyst Maury Raycroft maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $92 to $75.